Filtered By:
Specialty: Cardiology
Condition: Heart Failure

This page shows you your search results in order of relevance. This is page number 11.

Order by Relevance | Date

Total 4537 results found since Jan 2013.

New oral anticoagulants for stroke prevention in left ventricular hypertrabeculation/noncompaction?
Left ventricular hypertrabeculation/noncompaction (LVHT) is a cardiac abnormality of unknown etiology, associated with neuromuscular disorders, and an increased risk of heart failure, arrhythmias, and stroke or embolism (S/E) . We have shown that in 22 of 144 LVHT patients (15%) stroke (n=21) or peripheral embolism (n=1) had occurred. S/E etiology was either cardioembolic (n=14), atherosclerotic (n=5) or undetermined (n=3). Among the patients with cardioembolic S/E, 13/14 had either atrial fibrillation (AF) or systolic dysfunction . In a nested case–control study of patients with severe systolic dysfunction the stroke in...
Source: International Journal of Cardiology - April 19, 2013 Category: Cardiology Authors: Claudia Stöllberger, Josef Finsterer Tags: Letters to the Editor Source Type: research

Improving outcomes in patients with atrial fibrillation: Rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial
Conclusion EAST will determine whether rhythm control therapy, when applied early after the initial diagnosis of AF, can prevent cardiovascular complications associated with AF.
Source: American Heart Journal - October 20, 2014 Category: Cardiology Source Type: research

Stroke and Anticoagulation in Heart Failure Without Atrial Fibrillation: From Risk to Opportunity.
Abstract The association between heart failure and stroke risk has been described for more than three decades.(1) Hypercoagulability and left ventricular blood stasis are thought to contribute to stroke risk in patients with heart failure,(2) in addition to common risk factors such as hypertension and atrial fibrillation. Regardless of the mechanism, however, for the majority of patients with heart failure who do not have atrial fibrillation, this elevated stroke risk is appreciated but not managed. PMID: 25810335 [PubMed - as supplied by publisher]
Source: Circulation - March 25, 2015 Category: Cardiology Authors: Homma S, Ye S Tags: Circulation Source Type: research

Stroke prevention in atrial fibrillation: evidence from real-life studies
Atrial fibrillation (AF) is an increasing public health issue, especially owing to an accompanying five-fold increased risk of stroke. Anticoagulants are the cornerstone of therapy for stroke prevention in AF. The clinical benefits of vitamin K antagonists (VKAs; namely warfarin) shown in randomized controlled trials (RCTs) have been challenged when used in clinical practice by issues including the need for international normalized ratio (INR) monitoring, food and drug interactions, low time in the therapeutic range in substantial numbers of patients, and serious bleeding events. Combined, these have led to both an under-i...
Source: European Journal of Heart Failure Supplements - July 10, 2015 Category: Cardiology Authors: Akao, M., Beyer-Westendorf, J., Goto, S., Peterson, E. Tags: Articles Source Type: research

Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease
ConclusionThe placebo‐controlled cohort of heart failure patients with anaemia, diabetes mellitus, and chronic kidney disease from RED‐HF provides confirmation of the increased stroke risk associated with DA use identified in TREAT.
Source: European Journal of Heart Failure - October 1, 2015 Category: Cardiology Authors: Natalie A. Bello, Eldrin F. Lewis, Akshay S. Desai, Inder S. Anand, Henry Krum, John J.V. McMurray, Kurt Olson, Scott D. Solomon, Karl Swedberg, Dirk J. van Veldhuisen, James B. Young, Marc A. Pfeffer Tags: Original Article Source Type: research

Left Atrial Appendage Remodeling After Lariat Left Atrial Appendage Ligation Original Articles
Conclusions— Incomplete LAA ligation after Lariat is common. However, the remodeled LAA cavity is dramatically reduced. Diminished cavity size and tightening of the LAA orifice may play a role in the reduction of thrombus formation.
Source: Circulation: Arrhythmia and Electrophysiology - December 15, 2015 Category: Cardiology Authors: Kreidieh, B., Rojas, F., Schurmann, P., Dave, A. S., Kashani, A., Rodriguez-Manero, M., Valderrabano, M. Tags: Arrhythmias, Remodeling, Computerized Tomography (CT), Cerebrovascular Disease/Stroke Original Articles Source Type: research

Once-daily rivaroxaban for long-term stroke prevention in patients with atrial fibrillation
Oral anticoagulation is the long-term standard of care for preventing stroke in patients with atrial fibrillation (AF). However, anticoagulation is associated with an increased risk of bleeding, such that its use should be based on the absolute risks of stroke and bleeding, and the relative benefit–risk profile of the individual patient. Non-vitamin K antagonist oral anticoagulants, including rivaroxaban, are alternatives to vitamin K antagonists such as warfarin in this setting, and are supported in treatment guidelines as the optimal choice for patients with AF at moderate to high risk of stroke. Rivaroxaban can be...
Source: European Journal of Heart Failure Supplements - April 20, 2016 Category: Cardiology Authors: Antoniou, S., Amara, W. Tags: Articles Source Type: research

Reply Comparing the ATRIA, CHADS 2 , and CHA 2 DS 2 -VASc Scores for Stroke Prediction in Atrial Fibrillation
We tested the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation), CHADS2 (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke), and CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischemic attack, vascular disease, age 65 to 74 years, female) stroke risk scores in the CPRD (Clinical Practice Research Datalink) cohort of incident atrial fibrillation (AF) patients not using oral anticoagulants (OAC) because these are the patients for whom physicians must make the OAC treatment decision (1). The mean patient follo...
Source: Journal of the American College of Cardiology - May 10, 2016 Category: Cardiology Source Type: research

Burden of stroke and other cardiovascular complications in patients with atrial fibrillation hospitalized in France
Conclusion Half a million patients with AF were hospitalized in France in 2012. Cardiovascular-related hospitalizations involved half of these admissions, for a global burden of almost 2 billion, equivalent to 2.6% of total expenditure in French hospitals. Among these hospitalizations stroke/TIA/SE represented costly, but potentially preventable, complications.
Source: Europace - May 11, 2016 Category: Cardiology Authors: Cotte, F.-E., Chaize, G., Gaudin, A.-F., Samson, A., Vainchtock, A., Fauchier, L. Tags: Atrial fibrillation Source Type: research

Catheter ablation of atrial fibrillation in patients with heart failure: impact of maintaining sinus rhythm on heart failure status and long-term rates of stroke and death
Conclusion Long-term success rates for persistent (but not paroxysmal) AF ablation are significantly lower in HF patients. Left ventricular function and HF symptoms were improved following ablation. In HF patients, recurrent arrhythmia strongly predicted stroke and death during follow-up.
Source: Europace - May 24, 2016 Category: Cardiology Authors: Ullah, W., Ling, L.-H., Prabhu, S., Lee, G., Kistler, P., Finlay, M. C., Earley, M. J., Sporton, S., Bashir, Y., Betts, T. R., Rajappan, K., Thomas, G., Duncan, E., Staniforth, A., Mann, I., Chow, A., Lambiase, P., Schilling, R. J., Hunter, R. J. Tags: Ablation for atrial fibrillation Source Type: research

Echocardiographic parameters versus CHA2DS2-VASc score in prediction of overall cardiac events, heart failure, and stroke in non-valvular atrial fibrillation.
CONCLUSIONS: Echocardiographic parameters offer incremental value over CHA₂DS₂-VASc score for prediction of future cardiac events in NVAF. PMID: 28714523 [PubMed - as supplied by publisher]
Source: Cardiology Journal - July 17, 2017 Category: Cardiology Authors: Yang LT, Tsai WC, Su HM Tags: Cardiol J Source Type: research

Stroke risk in patients with device-detected atrial high-rate episodes.
Abstract Cardiovascular implantable electronic devices (CIEDs) can detect atrial arrhythmias, i. e. atrial high-rate episodes (AHRE). The thrombo-embolic risk in patients showing AHRE appears to be lower than in patients with clinical atrial fibrillation (AF) and it is unclear whether the former will benefit from oral anticoagulants. Based on currently available evidence, it seems reasonable to consider antithrombotic therapy in patients without documented AF showing AHRE >24 hours and a CHA2DS2-VASc score (congestive heart failure, hypertension, age ≥75 years [doubled], diabetes mellitus, prior stroke [...
Source: Netherlands Heart Journal - October 20, 2017 Category: Cardiology Authors: Erküner Ö, Rienstra M, Van Gelder IC, Schotten U, Crijns HJGM, Luermans JGLM Tags: Neth Heart J Source Type: research

Oral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios
Publication date: September 2018Source: IJC Heart & Vasculature, Volume 20Author(s): Ting-Yung Chang, Jo-Nan Liao, Tze-Fan Chao, Jennifer Jeanne Vicera, Chin-Yu Lin, Ta-Chuan Tuan, Yenn-Jiang Lin, Shih-Lin Chang, Li-Wei Lo, Yu-Feng Hu, Fa-Po Chung, Shih-Ann ChenAbstractAtrial fibrillation (AF) has become the most prevalent arrhythmia and it will increase the risk of ischemic stroke, heart failure, mortality, sudden cardiac death, myocardial infarction, and dementia. Stroke prevention with oral anticoagulant is crucial for management of AF patients. Vitamin K antagonist, which inhibits the clotting factors II, VII, IX and X...
Source: IJC Heart and Vasculature - September 1, 2018 Category: Cardiology Source Type: research

Edoxaban for the prevention of stroke in patients with atrial fibrillation.
Authors: Cervantes CE, Merino JL, Barrios V Abstract INTRODUCTION: Edoxaban is the last direct oral anticoagulant marketed for the prevention of stroke among patients with nonvalvular atrial fibrillation (AF). Areas covered: ENGAGE AF-TIMI 48 was the pivotal clinical trial that led to the approval of edoxaban 60 mg once daily. After the publication of this study, a great number of substudies and post hoc analyses have been published, together with some observational studies. The aim of this review was to update the current evidence about the use of edoxaban in AF patients. Expert commentary: In the ENGAGE AF-TIMI 4...
Source: Expert Review of Cardiovascular Therapy - March 24, 2019 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research

High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study.
CONCLUSIONS: Elevated hs-TnI is strongly associated with increased global CVD incidence in the general population independent of traditional risk factors. hs-TnI and high-sensitivity troponin T provide complementary rather than redundant information. PMID: 31030544 [PubMed - as supplied by publisher]
Source: Circulation - April 28, 2019 Category: Cardiology Authors: Jia X, Sun W, Hoogeveen RC, Nambi V, Matsushita K, Folsom AR, Heiss G, Couper DJ, Solomon SD, Boerwinkle E, Shah A, Selvin E, de Lemos JA, Ballantyne CM Tags: Circulation Source Type: research